OMIC vs. KEQU, FEIM, AKYA, SEER, INTT, MASS, OPTX, OWLT, CLIR, and RPID
Should you be buying Singular Genomics Systems stock or one of its competitors? The main competitors of Singular Genomics Systems include Kewaunee Scientific (KEQU), Frequency Electronics (FEIM), Akoya Biosciences (AKYA), Seer (SEER), inTEST (INTT), 908 Devices (MASS), Syntec Optics (OPTX), Owlet (OWLT), ClearSign Technologies (CLIR), and Rapid Micro Biosystems (RPID). These companies are all part of the "measuring and control equipment" industry.
Singular Genomics Systems vs.
Singular Genomics Systems (NASDAQ:OMIC) and Kewaunee Scientific (NASDAQ:KEQU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.
Kewaunee Scientific has higher revenue and earnings than Singular Genomics Systems. Singular Genomics Systems is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kewaunee Scientific had 1 more articles in the media than Singular Genomics Systems. MarketBeat recorded 4 mentions for Kewaunee Scientific and 3 mentions for Singular Genomics Systems. Kewaunee Scientific's average media sentiment score of 0.63 beat Singular Genomics Systems' score of 0.32 indicating that Kewaunee Scientific is being referred to more favorably in the news media.
65.8% of Singular Genomics Systems shares are owned by institutional investors. Comparatively, 32.7% of Kewaunee Scientific shares are owned by institutional investors. 22.2% of Singular Genomics Systems shares are owned by company insiders. Comparatively, 14.2% of Kewaunee Scientific shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Singular Genomics Systems currently has a consensus price target of $10.75, suggesting a potential downside of 45.94%. Given Singular Genomics Systems' stronger consensus rating and higher probable upside, equities analysts clearly believe Singular Genomics Systems is more favorable than Kewaunee Scientific.
Kewaunee Scientific received 129 more outperform votes than Singular Genomics Systems when rated by MarketBeat users. Likewise, 67.94% of users gave Kewaunee Scientific an outperform vote while only 44.83% of users gave Singular Genomics Systems an outperform vote.
Singular Genomics Systems has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Comparatively, Kewaunee Scientific has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500.
Kewaunee Scientific has a net margin of 9.39% compared to Singular Genomics Systems' net margin of -3,237.89%. Kewaunee Scientific's return on equity of 25.83% beat Singular Genomics Systems' return on equity.
Summary
Kewaunee Scientific beats Singular Genomics Systems on 11 of the 17 factors compared between the two stocks.
Get Singular Genomics Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMIC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Singular Genomics Systems Competitors List
Related Companies and Tools
This page (NASDAQ:OMIC) was last updated on 2/1/2025 by MarketBeat.com Staff
